Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Open Label Study to Compare the Complete Pathological Response Rate Achieved With 4 Combinations of Herceptin, Docetaxel and Pertuzumab in Patients With Locally Advanced, Inflammatory or Early Stage HER2 Positive Breast Cancer

Trial Profile

A Randomized, Open Label Study to Compare the Complete Pathological Response Rate Achieved With 4 Combinations of Herceptin, Docetaxel and Pertuzumab in Patients With Locally Advanced, Inflammatory or Early Stage HER2 Positive Breast Cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Nov 2018

At a glance

  • Drugs Pertuzumab (Primary) ; Docetaxel; Trastuzumab
  • Indications Early breast cancer
  • Focus Therapeutic Use
  • Acronyms NEOSPHERE
  • Sponsors Roche
  • Most Recent Events

    • 14 Nov 2018 Results presented at the 21st Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
    • 31 Aug 2018 Biomarkers information updated
    • 05 Jan 2017 Results of data from the safety populations of three trials (NEOSPHERE, CLEOPATRA and TRYPHAENA) published in the Annals of Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top